Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

Hims & Hers shows platform expansion, verticalization, new Labs offerings, slower FCF growth and strong long-term revenue targets. Learn why HIMS stock is a buy.

Throughout 2024, Hims & Hers demonstrated consistent top-line acceleration driven by new product introductions and broader consumer adoption. The company’s revenue grew from $260 million in Q1 2024 to ...

Hims & Hers Health stock has seen its fair value estimate trimmed from about $46.00 to roughly $44.36 per share, even as analysts grow more optimistic about its long term revenue trajectory. Stronger ...

If you are wondering whether Hims & Hers Health is still a smart buy after its big run, you are not alone. This stock has quickly moved from a niche telehealth play to one of the market's more talked ...

Shares of Hims & Hers Inc. fell after hours on Monday after the wellness and telehealth platform's third-quarter forecast came up shy of Wall Street's estimates, although the company stuck with its ...

Hims & Hers reported strong financial results for the first quarter of 2025, with revenue rising 111% year-over-year to $586.0 million. Net income for the quarter was $49.5 million, up from $11.1 ...

Hims & Hers Health (HIMS) has been one of the market’s standout growth stocks in recent years. The company has successfully built a direct-to-consumer health platform targeting conditions like hair ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, has recently announced its Q1 financial results, showing notable year-over-year growth. The company reported adjusted earnings per share of ...